Canadian eCLIPs™ Safety and Feasibility Study Protocol

Exclusion Criteria

• •1. Patient who presents with an intracranial mass or currently undergoing radiation therapy for carcinoma of the head or neck region.
• •2. Patient with an International Normalized Ratio (INR)≥ 1.5.
• •3. Patient with serum creatinine level ≥104 µmol/L at time of enrolment.
• •4. Patient with a platelet count ˂100x103 cells/mm3 or known platelet dysfunction at time of enrolment
• •5. Patient who has a known cardiac disorder, likely to be associated with cardioembolic symptoms such as AFIB (atrial fibrillation)
• •6. Patient with any condition which in the opinion of the treating physician would place the participant at a high risk of embolic stroke
• •7. Patient with known allergies to nickel-titanium metal
• •8. Patient with known allergies to aspirin, heparin, ticlopidine, or clopidogrel
• •9. Patient with a life threatening allergy to contrast (unless treatment for allergy is tolerated)
• •10. Patient with inappropriate anatomy as demonstrated by angiography due to severe intracranial vessel tortuosity or stenosis, or intracranial vasospasm not responsive to medical therapy.
• •11. Patient who is currently participating in another clinical research study.
• •12. Patient who has had a previous intracranial stenting procedure associated with the target aneurysm.
• •13. Patient who is unable to complete the required follow-up.
• •14. Patient who is pregnant or breastfeeding.
• •15. Patient who has participated in a drug study within the last 30 days.